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Background: Occult HBV infection (OBI) is defined by the persistence of HBV in the liver without serum HBsAg
and HBVDNA. It represents a life-threatening event during immunosuppressive chemotherapies. An OBI occurs
in approximately 18% of HBcAb + patients. International guidelines suggest surveillance for HBV markers in
immunosuppressed patients. In Non-Hodgkin Lymphoma (NHL), the prevalence of OBI reactivation remains to
be established.
Methods: In order to determine the prevalence of occult HBV reactivation in a large cohort of patients during
chemotherapy for NHL, we analysed 498 NHL patients in a centre of Southern Italy. We evaluated HBV markers,
NHL type, treatment type and occurrence of HBV reactivation.
Results: Forty % of patients were treated with monoclonal antibodies and 60.3% without. Ninety-six patients
were HBcAb+, HBsAg-. HBV reactivation occurred in ten subjects of this subgroup. All of them were successfully
treated with Lamivudine. None of the patients experienced liver-related death. The prevalence of OBI reactivation
was of 10.42% in HBcAb + HBsAb- patients. This event occurred in 50% of patients treated with mild immunosup-
pressive therapies. Each reactivation was treated with Lamivudine.
Discussion: This report suggests that a strict surveillance is important and cost-effective in HBcAb + HBsAg- NHL
patients treated with mild immunosuppressive therapies, in order to detect an occult HBV reactivation.
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“Occult” HBV infection represents a particular clinical en-
tity that is characterized by the persistence of HBV DNA
in the liver tissue, without the evidence of overt HBV
infection, in individuals who are HBsAg negative and
HBcAb positive or negative [1]. It has also been episodic-
ally reported in HBsAb positive patients [2]. Its character-
istics are: the absence of HBV DNA [or eventually
transient presence of very low levels of viraemia] in the
serum, and the persistence in the liver of the “covalently
closed circular DNA” (cccDNA), a long-lasting HBV repli-
cation intermediate that can be revealed only by very* Correspondence: mpersico@unisa.it
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unless otherwise stated.sensitive techniques like “nested-PCR”, performed on liver
tissue [1]. It is an “elusive” infection, the real prevalence of
which in the general population is not known, being quite
variable depending on the different geographical areas
and study populations [3]. However, few studies report
that the prevalence of OBI is approximately 16%-18%
in subjects with evidences of previous HBV infection
(i.e. HBcAb positive/HBsAg negative patients) and of 7-8%
in subjects totally seronegative for HBV [4-6]. What is well
known about this silent infection is that it can represent a
life-threatening risk factor if the carrier experiences an im-
munosuppression. In fact, when the host immune surveil-
lance is low, an overt HBV reactivation can occur [2]. In
this case, the patient has titrable HBsAg and HBV DNA in
the serum and, as soon as the immune surveillance is re-
constituted at the end of chemotherapy, he develops anral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with ALT elevation and only minimal lesions, to fulminant
liver failure and death. Therefore, any patient who
carries the OBI, and necessitates a chemotherapy-
immunotherapy, should undergo to pre-emptive antiviral
therapy with nucleoside/nucleotide analogues that have
demonstrated to be efficacious in preventing HBV reacti-
vation in various immunosuppressive settings [7-15]. The
core of the problem is that OBI cannot be easily diagnosed
and, for this reason, any HBcAb positive/HBsAg nega-
tive patient should be considered a possible occult in-
fection carrier. What we know from literature is that
onco-hematological diseases have the major risk of OBI
reactivation, because of the strong immunosuppression
experienced by the patients, due to both the disease itself
and the chemotherapy [2]. In particular, in non-Hodgkin
lymphoma (NHL), occult HBV reactivation has been re-
ported to occur in 3% to 25% of patients, depending on
the pharmacological and geographical settings [16-20].
Even if the real prevalence remains to be established,
American Association for the Study of Liver Diseases
(AASLD) recommended periodical monitoring of serum
HBsAg and HBV-DNA, [21] whereas European Associ-
ation for the Study of the Liver (EASL) recommended
monitoring with serum ALT and eventually HBV-DNA
assays in these patients [22]. The Italian association for
the Study of the Liver (AISF) also published its recom-
mendation in 2007 indicating two different strategies:
for mild haematological therapies (standard protocols
without monoclonal antibodies) HBsAg monitoring was
advised, whereas in subjects treated with intense im-
munosuppression (i.e. protocols including monoclonal
antibodies and/or strongly immunosuppressive therapies,
i.e. “dose dense” regimens) universal prophylaxis was indi-
cated. Nevertheless the strength of the recommendation
was low (B and C) and derived from retrospective studies.
Further studies where encouraged in HBcAb positive pa-
tients [23].
This single-center retrospective study was designed to
determine the prevalence of occult HBV reactivation in
HBsAg-negative and HBcAb-positive carriers who under-
went immunosuppressive treatments for malignant lymph-
omas in a large cohort of patients from Southern Italy.
Methods
From January 2005 to December 2011 we enrolled 498
consecutive patients admitted to the Haematology
Division of Federico II University of Naples for treat-
ment of Non-Hodgkin lymphoma.
Exclusion criteria were: the presence of any haemato-
logical malignancy other than Non-Hodgkin Lymphoma,
previous immunosuppressive treatments of any kind
(organ transplant, autoimmune therapies, other malig-
nancies), HIV infection.Each patient gave an informed consent, and the study
was approved by the Ethics Committee of the University
of Salerno. Non-Hodgkin lymphoma was diagnosed from
histological findings (i.e. lymph nodes, bone marrow, etc.)
according to the Revised European-American Lymphoma
(REAL) classification criteria revised by Harris [24]. It was
classified according to the REAL classification and grouped
into indolent or aggressive lymphomas [25]. Ann Arbor
classification stage was determined for all patients at the
onset of the neoplastic disease by physical examination,
total body computed tomography scan and bone marrow
biopsy. Cheson’s criteria were used to define the response
to antineoplastic treatment [26].
Prior to start NHL treatment every single patient under-
went a physical examination, complete blood count, ALT
and AST, routine biochemistry assays, HBsAg, HBcAb,
HBeAg, HBeAb, HBsAb, HAVAb IgM (antibodies by ELISA
Orthodiagnostic system), HCV-Ab (with commercial en-
zyme linked immunosorbent assay III, Abbot laboratories
Chicago). HBV-DNA with Real-Time PCR (LightCycler
Instrument, Roche Molecular Biochemicals, Mannheim,
Germany), was also performed in patients who were already
HBsAg positive patients before NHL treatment.
All HBsAg positive patients were evaluated by a skilled
hepatologist who assessed the liver disease status and
performed the correct follow-up of the liver functional-
ity. Every patient who was HBsAg positive underwent to
chemotherapy after a pre-emptive therapy with NUCs
was assured, as indicated by international guidelines.
Pre-emptive therapy started at least in a time interval
between two weeks before and the first day of chemother-
apy (depending on the urgency to initiate NHL treatment),
and continued throughout the whole time of chemother-
apy, and at least 12 months later. An HBV-DNA assay
was performed every 2 months during treatment and
16 months later. Every HBcAb positive, HBsAg/HBsAb
negative patient underwent to monthly ALT monitoring
during therapy and throughout 16 months after. All the
others patients underwent to a monthly ALT monitoring
during therapy and at least every 3 months in the follow
up. Thereafter every patient underwent to twice a year
liver ALT evaluation. If the patient experienced an ALT
derangement more than twice upper normal value (UNV),
complete blood tests were performed to search liver-
bound viruses: HBV-DNA, EBV-DNA, HCV-RNA, CMV-
DNA and HSV-RNA 1 and 2 assays were investigated.
If the patient experienced a probable OBI reactivation
(see the diagnostic criteria below), Lamivudine therapy
was promptly started at the standard dosage. At OBI
reactivation ALT monitoring was performed every two
weeks and complete liver functionality tests (compre-
hending also HBV-DNA quantitative assay) were per-
formed monthly. The study protocol is shown in
Figure 1.
Figure 1 Diagnostic/therapeutic flow-chart. Every patients underwent to HBV status assessment prior to start chemotherapy. HBsAg positive
patients underwent to NUCs pre-emptive therapy. Monitoring of ALT continued monthly for every patient during treatment and at least
16 months after treatment interruption. If there were an ALT elevation, HBV-DNA and HBsAg assays were performed to diagnose probable OBI
reactivation. At the diagnosis of probable OBI reactivation a “rescue therapy” with lamivudine was promptly started. In patients who reactivated, ALT
every two weeks and a monthly complete liver functionality test plus HBV-DNA assay were performed. In patients who reactivated, Lamivudine was
continued until the complete HBV remission (see diagnostic criteria in the Methods section).
Masarone et al. BMC Gastroenterology 2014, 14:31 Page 3 of 10
http://www.biomedcentral.com/1471-230X/14/31Definition of HBV/OBI reactivation
An “HBV reactivation” was diagnosed when a patient ex-
perienced an ALT/AST derangement (at least 2x upper
normal values) with HBsAg and HBV-DNA detectable
in the serum (>2000 UI/mL), without any contemporary
possible cause of liver disease. A “probable OBI reactiva-
tion” diagnosis was performed when diagnostic criteria
above exposed were applicable to a patient who was
HBsAg negative before NHL treatment (reverse serocon-
version), and any other cause of liver functionality de-
rangements was excluded as described above. In these
patients a HBV DNA assay was performed on blood
samples collected and frozen prior to start treatment, at
the time of enrolment.Cost effectiveness analysis
A cost effectiveness analysis was performed to evaluate
the more effective approach between universal prophylaxis
and monitoring to prevent OBI reactivation risk in HBcAb
positive patients undergone to Rituximab containing pro-
tocols. We used the “Diagnosis Related Group system”
(DRG), that is used to assess the healthcare costs in our
country [27].Statistical analysis
Statistical analyses were performed using the Statistical Pro-
gram for Social Sciences (SPSS®) ver.16.0 for Macintosh®
(SPSS Inc., Chicago, Illinois, USA). Student t-test and
Mann-Whitney U test were performed to compare con-
tinuous variables, chi-square with Yates correction or
Fisher-exact test to compare categorical variables. Stat-
istical significance was defined when “p < 0,05” in a
“two-tailed” test with a 95% Confidence Interval.Results and discussion
Demographical characteristics of our study population is
shown in Table 1. Of the 498 patients, 45,4% were fe-
males and 54,6% males, with a mean age of 61 years
(SD ± 14). 52,7% of these patients had an aggressive
lymphoma and 47,3% an indolent lymphoma according to
Percy et al. [22]. Four hundred and 76 (95,58%) patients
had B-cell lymphoma, 22 (4,41%) patients had T-cell
lymphoma. Thirty-eight pts (7,6%) were HBsAg positive.
Of these patients, 6 (15,78%) were inactive carriers
(HBsAg positive with HBVDNA < 2000 UI/mL and nor-
mal ALT), 32 (84,22%) had an HBV active disease, no one
had decompensated cirrhosis. Moreover, 15 (39,47%) were
Table 1 Demographical characteristics of the study population
Variable Overall HBsAg positive HBsAg negative p
No. of patients 498 38 460 -
Age - Mean [±SD] 61,00 [±14,05] 55,42 [±13,62] 57,32 [±14,95] 0,45
Sex – M/F M: 54,40% - M: 57,89% M: 47,83% 0,23
F: 45,40% F: 42,11% F: 52,17%
No. of patients HBsAb + 90 [18,07%] 0 90 [19,56%] 0,003
No. of patients HBcAb +/ HBsAg - 134 [26,90%] 0 96 [20,86%] 0,002
No. of patients HBcAb - / HBsAg - 274 [55,03%] 0 274 [59,56%]
Lymphoma type Indolent: 47,3% - Indolent: 33,35% - Indolent: 44,34% - 0,22
Aggressive: 52,7% Aggressive: 66,65% Aggressive: 55,66% 0,22
Rituximab therapy Yes: 60,30% - Yes: 18 [47,37%] Yes 262 [56,95%] 0,25
No: 39,70% No: 20 [52,63%] No: 198 [43,04%]
HBV reactivation 10 [2,01%] 0 10 [2,17%] 0,22
NUC profilaxys/rescue therapy 38/10 38/0 0/10 <0,0001
“Per year Incidence of reactivation”
[mean ± SD]
1,71% 0 2,04% <0,0001
±2,43% ±2,97
Liver related decompensations/
hospitalizations/deaths
0% 0% 0% -
In the first column overall patients characteristics: HBV reactivation occurred in 2,01% of cases. In the second and third column demographical characteristics of
HBsAg positive and negative patients, respectively. HBV reactivation occurred in HBsAg negative patients only, due to the NUC profilaxys performed in HBsAg
positive patients [see Methods]. (Chi-square, Pearson corrected calculations for all variables, Age: student t-test).
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LAM+ADF, 5 with ETV, 5 with TFV), 17 where consid-
ered to have mild liver disease and were not under anti-
viral treatment at the time of NHL diagnosis. HBsAg
positive patients not already in treatment with NUCs,
were posed in pre-emptive antiviral therapy with nucleo-
side analogues. Ninety-six out of 498 patients (19,27%)
were HBcAb positive and HBsAg negative. This preva-
lence is higher prevalence in respect to the general popu-
lation, but has already been described in NHL patients
[28]. No statistical relevant differences were found be-
tween HBsAg positive and HBsAg negative patients except
for the HBV reactivations that occurred only in HBsAg
negative patients, as described above. Ninety (18,07%) pa-
tients were HBsAb positive, and underwent to the same
monitoring as the totally HBV negative ones. Of these, 30
subjects were HBsAb and HBcAb positive, and therefore
were likely to have spontaneously recovered from an HBV
infection. The remaining 60 subjects were HBsAb positive
only, and therefore likely vaccinated.
Therapy type
On the basis of the clinical assessment of the lymphoma,
39,7% of the patients underwent anti-neoplastic treatments
protocols that included rituximab or high immunosuppres-
sive drugs or dosages, 60,3% followed conventional treat-
ment protocols not including highly immunosuppressive
drugs or “dose dense” regimens [23]. Due to the retrospect-
ive nature of the present study the prevalence of Rituximab-containing protocols is slightly lower than that observed in
the actual clinical practice. In HBcAb positive-HBsAg nega-
tive patients NHL chemotherapy protocols included Rituxi-
mab in 50%. Table 2 reports on this class of patients.
No statistical significant differences were found be-
tween patients treated with and without Rituximab in
this subgroup, except for the different rates of aggressive
lymphomas that were more frequently treated with
Rituximab.
HBV reactivation/OBI reactivation
A mild ALT (mean 113,44 ± 61,35 U/dL) derangement
was found during treatment in 47 patients (9,44%) with-
out evidence of any liver infection and this was attrib-
uted to an effect of chemotherapy.
No OBI reactivations were diagnosed in HBsAb posi-
tive, in HCVAb positive and totally negative patients.
A probable OBI reactivation was observed in 10 pa-
tients out of 96 HBcAb positive-HBsAg negative patients
(10,42%), who had clinical and laboratory characteristics
compatible with HBV reactivation criteria described
above (see Methods section). Characteristics of the 10
reactivated patients are summarized in Table 3.
Of the reactivated patients (6 M, 4 F, mean age 63 y,
SD ± 8), 2 had T–cell NHL and 8 B NHL (3 MALT, 5
Diffuse Large B cells). Of these subjects, 5 (5,21%) had
been treated with Rituximab (3 with CHOP-R protocol,
1 with Fludarabin and Rituximab, 1 with Fludarabin +
Novantrone + Rituximab) and 5 (5,21%) without (2 with
Table 2 HBcAb positive “only” patients characteristics
Rituximab containing protocols
Variable Overall Yes No p
No. of patients 96 48 48 ns
Age - Mean [±SD] 64,39 ± 9,63 65,17 ± 10,21 64,02 ± 8,37 ns
Sex – M/F M: 57 M: 30 M: 27 ns
F: 39 F: 18 F: 21
Lymphoma type Indolent: 50 Indolent: 17 Indolent: 33 0,001
Aggressive: 46 Aggressive: 31 Aggressive: 15
Probable OBI reactivation 10 [10,42%] 5 [10,42%] 5 [10,42%] ns
NUC profilaxys/rescue therapy 0/10 0/5 0/5 ns
“Per year Incidence of reactivation” [mean ± SD] 8,23% ± 9,84 9,08% ± 10,69 11,54% ± 40,74 ns
Reactivation time [mean weeks after therapy] 26,67 ± 12,20 31,60 ± 14,50 20,50 ± 4,72 ns
Liver related decompensations/hospitalizations/deaths 0% 0% 0% -
No statistical differences were found in patients treated with ad without Rituximab. (Chi-square, Pearson corrected calculations for all variables, Age, incidence of
reactivation and reactviation time: student t-test).
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CEOP). Each patient experienced reactivation after the
end of chemotherapy cycle then, as expected, after the
immune response restoration. The mean time of the ap-
pearance of HBV reactivation was 26,67 (±12,21) weeks.Reactivation risk
In the overall population, the Relative Risk (RR) of de-
veloping a HBV reactivation by the use of Rituximab-
containing protocols was of 1.540 (95% C.I.: 0.481-4.930)
in respect of standard chemotherapies (p:0.525). In
HBcAb +HBsAg- patients, RR was equal to 1.000, since
reactivation occurred with the same frequency in pa-
tients treated with and without Rituximab.
To adequately address the risk of a pOBI reactivation in
our 96 patients HBcAb +HBsAg, we carried out a multi-
variate analysis (performed by a binary logistic regression
model) to analyse the factors that could affect its appear-
ance. In particular, we analysed: age, sex, lymphoma type,
grading, staging and the use of Rituximab-containing pro-
tocols as independent variables and pOBI reactivation as
dependent variable. None of the analysed factors reached
statistical significance as an independent factor influen-
cing the occurrence of reactivation (see Additional file 1).Outcome and follow-up
Every patient who reactivated HBV infection was rapidly
treated with nucleoside analogue Lamivudine experien-
cing a fast viral response with HBVDNA negativization
with a mean time of 5,72 (±2,05) weeks. None had liver
decompensation symptoms and signs, nor did any of
them need hospitalization. In the follow-up, 2 patients
died for NHL complications, 3 patients had NHL remis-
sion, 2 patients had NHL relapse and were treated again,5 patients are already in follow-up. None experienced
liver-related death in this group.
Because of the small number of patients who reacti-
vated infection, we cannot make a statistically valid com-
parison with patients who did not reactivated, in terms
of NHL-related mortality and morbidity. Moreover, due
to the fact that we included various histological types of
NHL in the present study, report data on overall mortal-
ity and morbidity may be methodologically wrong, and
to report on mortality rate of every histological type on
NHL falls out of the aims of the present study.
Cost-effectiveness analysis
As reported above, according to AISF indications,
HBcAb positive/HBsAg negative patients treated with
Rituximab and/or “dose dense” regimens should undergo
to universal prophylactic antiviral therapy with NUCs
during NHL treatment [22]. In our series, the recurrence
rate of HBV reactivation in HBcAb positive subjects was
found to be 10,42%, and this event wasn’t related to an
increase in mortality rate. For this reason our cost bene-
fit analysis, comparing the potential costs of Lamivudine
prophylaxis in 48 HBcAb positive HBsAg negative pa-
tients treated with rituximab, and the costs of an even-
tual HBV reactivation in terms of hospitalization costs,
reported an advantage in the “monitoring” approach that
was used in our patients in respect to universal prophy-
laxis. Data are reported in Table 4.
Based on these data, we compared HBcAb positive pa-
tients who reactivated infection with those who did not,
to search for any event predictors, so to obtain a staging
of the risk of reactivation. None of the analysed charac-
teristics, such as age, sex, the type and the degree of
lymphoma, the type and duration of chemotherapy,
proved to be statistically different in the two groups,
Table 3 Characteristicsof “HBVreactivated” patients. 10 patients over 498 had HBV reactivation
Patient
no.
Age
(years) Sex
Stage of
lymphoma
Indolent
aggressive
(0-1)
Baseline
At diagnosis of
HBV reactivation
Time of
diagnosis of HBV
Reactivation
Time to
HBV
recovery
Nuc
therapy
duration
Follow up
HBsAg
status Outcome
HBs-
Ag
HBV- DNA
(UI/μL)
ALT
(U/L)
Rituximab
(yes/no) Therapy
HBV- DNA
(UI/μL)
Peak ALT
(XN.V.)
Weeks after
NHL therapy
Weeks
after NUC
start
Weeks Pos/neg
1 50 F IV 1 - 0 23 y CHOP-R 350.000 4,5x 40 4 28 Neg
Alive (NHL
remission)
2 73 M IV 0 - 0 26 n VNCOP-B 450.000 10x 24 8 Ongoing Neg
Alive (NHL
relapse)
3 64 F I 1 - 0 34 y Fludara-R 650.000 12x 12 4 22 Neg
Alive (NHL
remission)
4 62 M 1 - 0 22 y CHOP-R 130.000 4x 44 3 Ongoing Pos
Alive (NHL
relapse)
5 50 F II 1 - 0 28 y CHOP-R 910.000 20x 20 8 44 Neg
Alive (NHL
remission)
6 71 M IV 0 - 0 19 n CHOP 160.000 11x 24 6 48 Neg
NHL related
death
7 66 M 0 - 0 36 n VNCOP-B 170.000 3,7x 20 Ongoing Pos Alive
8 70 M IV 0 - 0 31 y
Fludara
Nova -R
160.000 5,4x 72 Ongoing Pos Alive
9 52 F I 0 - 0 29 n CHOP 550.000 6,1x 14 7 46 Neg Alive
10 60 M IV 0 - 0 34 n
CEOP, Gem,
VNCOP-B
340.000 6x
Until
death
Pos
NHL related
death
Of this group, everyone had HBcAb positive, HBsAg, HBsAb and HBVDNA negative status prior to start NHL therapy. Five patients were treated with Rituximab-containing protocols and five without. The mean time to
HBV reactivation was 26,67 (±12,21) weeks. The mean time to HBV recovery (HBVDNA negativization and normal ALT) was 5,71 (±2,06) weeks. Five patients had HBsAg negativization after a mean time of NUC therapy
of 37,80 (±11,78) weeks and stopped NUC therapy. Five patients were already in NUC therapy at the end of follow-up, due to HBV infection persistence (HBsAg positivity) and/or NHL relapse. Patient 7 to 10 have
missing data, because of the retrospective nature of this study.
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Table 4 Cost-benefit analysis of prophylaxis in respect to HBV reactivation by “Diagnosis Related Group” system in our
48 HBcAb positive HBsAg negative patients treated with Rituximab
Unitary cost n. patients Total per patient Duration [days] Total
Cost of prophylaxis
Lamivudine € 3,18 48 € 152,64 360 € 54.950,40
HBV DNA monitoring € 130,00 48 € 6.240,00 6 € 37.440,00
HBsAg monitoring € 17,00 48 € 816,00 6 € 4.896,00
AST/ALT monitoring € 5,74 48 € 275,52 12 € 3.306,24
Total € 155,92 48 € 7.484,16 € 100.592,64
Cost of HBV Reactivation
HBV DNA monitoring € 130,00 48 € 6.240,00 6 € 37.440,00
AST/ALT monitoring € 5,74 48 € 275,52 12 € 3.306,24
Cost of DRG 205 [v24 Grouper] € 3.769,10 5 - - € 18.845,50
Total € 3.904,84 - - - € 40.746,24
Drg 205: Liver disease except malignancies, cirrhosis, alcoholic hepatitis with cirrhosis.
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vated which reduced the power of statistical tests.
Discussion
Our study reports a prevalence of “probable OBI reacti-
vation” in NHL patients. It has to be noticed that this
prevalence is similar to the supposed prevalence of OBI
infection in blood donors in the same area [29-44]. This
finding may confirm the general conviction that onco-
haematological patients are at high risk of HBV reactiva-
tion if they are OBI carriers. We reported about a “prob-
able OBI reactivation” because in in this large retrospective
study we did not collect liver specimens, and consequently
we cannot confirm the presence in the liver extracts of al-
most two out of three HBVgenes (core, X, surface) in pa-
tients who reactivated infection, which has been defined as
the diagnostic criterion of OBI [1]. Nevertheless, we can
safely assign the HBV events occurred in our patients to
an OBI infection reactivation, because of the finding of
HBVDNA negativity at the time of the NHL diagnosis.
HBVDNA assays were performed with very sensitive
methods such as CobasTaqman PCR, and for this rea-
son we can exclude that our patients were “false occult”
HBV infected patients, as described by Launay et al.
[44]. Moreover, we previously reported that in a small
group of HBcAb positive patients with available liver
biopsies specimens, OBI was found in tissue specimens
only in patients later experiencing a HBV reactivation
after chemotherapy [7].
The general agreement of International Liver Associa-
tions about the management of this type of patients is
well known [21-23]. In particular, even if a very careful
monitoring is suggested, different approaches are re-
ported, in particular regarding the type of anti-neoplastic
therapy. In fact, it has been reported that a slightly higher
prevalence of OBI occurs in patients treated with highlyimmunosuppressive treatments, in particular monoclonal
antibodies such as anti-CD20 antibody Rituximab [2]. Be-
cause of these findings, Italian Liver Association suggested
prophylaxis with Lamivudine in all HBcAb positive
HBsAg negative patients who are assigned to highly im-
munosuppressive treatments for haematological malig-
nancies [23]. This approach should be justified by the low
toxicity of orally administered Lamivudine. Nevertheless,
in our HBcAb-positive cohort, OBI reactivation occurred
in patients treated with Rituximab and also in patients in
whom it was not administered, with a prevalence higher
than that reported in other series. This may be due to the
different study populations and/or different therapy proto-
cols. In fact, it has to be noticed that two out of these 10
patients were treated with Fludarabin that is accounted
for high immunosuppression. For this reason, even if
the therapeutic approach in these two patients was not
based on a “dose-dense” protocol, it is likely that these
two patients experienced at least a “moderate” im-
munosuppression, intermediate between that of Rituxi-
mab and standard protocols. Our approach of strict
monitoring in all these patients was chosen in a time
(year 2005) when there were less indications from lit-
erature than today. Nevertheless, none had serious con-
sequences by this type of management. In fact, no
patient had liver decompensation, liver related hospitaliza-
tions or liver-related death. As reported in the results sec-
tion, 39,7% of our HBcAb positive HBsAg negative
patients were treated with Rituximab-including or dose
dense protocols. In this way, we should have used Lamivu-
dine as prophylactic treatment in all of them to prevent 5
events, which were safely managed without consequences.
Moreover, OBI reactivation occurred also in patients
undergone to “standard” treatments. If we refer to these
data, universal prophylaxis should have been applied to all
HBcAb positive HBsAg negative patient. At this point, a
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all the HBcAb positive HBsAg negative patients with
NUCs to prevent the OBI reactivation occurrence in a
small quote of them, or may it be more effective a “wait
and see” protocol? To assess this point, we performed a
cost-effectiveness analysis whose results are reported in
Table 4. We calculated the costs of prophylaxis in a time
interval of twelve months, which encompasses the time of
a standard Rituximab-containing chemotherapeutic proto-
col and a minimum time of follow-up. It has to be noticed
that very often NHL patients need more than one therapy
cycle to obtain NHL remission, and sometimes, if they do
not obtain a complete remission, undergo to long-term,
low-dose, “maintenance” therapies with Rituximab. These
patients are at high risk of HBV reactivations due to the
long times of immunosuppression. Nevertheless, even if
our calculations underestimated the costs of prophylaxis,
the “monitoring approach” resulted cost-effective. More-
over, patients treated with standard protocols should have
been excluded from the eventual prophylaxis protocol.
Nevertheless, even if in our series HBV reactivation did
not lead to an increase in mortality/morbidity, this event
still remains a life-threatening risk for the patients. More-
over, even though in our series no serious events in terms
of morbidity and/or mortality occurred, in other literature
reports a monitoring approach did not guarantee patients
survival [16,45-49]. These detrimental results could be as-
cribed to the delayed start of NUC therapy if the monitor-
ing is not adequately strict(less than one evaluation/
month). Also, it has been reported that performing only
the transaminase evaluation should not be acceptable to
prevent severe reactivations [2]. Our monitoring approach
resulted efficacious probably because of the monthly ALT
assay was strictly observed.
Due to the retrospective nature of our study, we can-
not draw any firm conclusion on which should be the
best approach for patients with isolated HBcAb positiv-
ity who should undergo chemotherapeutic regimens
(universal prophylaxis vs monthly ALT monitoring). A
randomized controlled trial might be needed to properly
address this issue.
Discussion
Out of four-hundred-ninety eight NHL patients, HBV
reactivation occurred only in HBcAb+, HBsAg-, HBsAb-
subjects. None of the HBsAg + patients experienced such
a reactivation since all of them were treated with pre-
emptive Lamivudine therapy.
The rate of reported reactivation was similar either in
patients treated with low immunosuppressive therapy or
in those treated with high immunosuppressive therapy
(Rituximab).
A “monitoring” approach, being more cost-effective
than universal prophylaxis, should be chosen, either inlow or high immunosuppressive treated subjects and a
“rescue” antiviral treatment is advised in the case of re-
activation occurrence. Nevertheless, the reported failure
of rescue therapy [16,45-49] needs to be considered and
might represent a limitation.
The main limitation of the study is its retrospective
nature. A prospective randomized double bind trial is
warranted and, at present, the universal prophylaxis
should be considered the only possible approach.
Our study confirms the need of at least a strict surveil-
lance of these patients in order to prevent OBI reactiva-
tions, which is a life-threatening condition if not rapidly
recognized and treated.Additional file
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